Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.41 |
| ▸ | LPL | P06858 | 11/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 2/20 | 0.35 |
| ▸ | P4HB | P07237 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31207677 | 0.86 | LIPG (0.40) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL17905759 | 0.86 | LIPG (0.40) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL1129175 | 0.77 | LIPG (0.59) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL19652467 | 0.76 | LIPG (0.43) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL17903421 | 0.76 | LIPG (0.43) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL19652465 | 0.76 | LIPG (0.43) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL20110065 | 0.75 | FFAR1 (0.39) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL17903420 | 0.75 | LPL (0.49) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL28451953 | 0.75 | CYP2C19 (0.42) | — | |
| SCHEMBL20110049 | 0.74 | FFAR1 (0.38) | IRAK4LIPGLPLCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118766-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118766-A1 | BTK INHIBITORS | BTK, SYK, LYN | IRAK4 100/4885LIPG 1114/4885LPL 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.